October Pharma results, Q3 2024
Net profit, assets, equity and cash flow for Q3 2024, against the same period a year earlier, from the published financial statements.
Net profit32.04 millionEGP · −34.6% vs the same period a year earlier
Total assets1.47 billionEGP · +33.9% vs the same period a year earlier
Shareholders' equity649 millionEGP · +20.5% vs the same period a year earlier
Operating cash flow28.66 millionEGP · +47.5% vs the same period a year earlier
In short
- October Pharma's net profit for Q3 2024 was about 32.04 million EGP, down −34.6% from 49.02 million EGP in Q3 2023.
- Total assets at the end of Q3 2024 were about 1.47 billion EGP, and shareholders' equity about 649 million EGP.
- Operating cash flow for Q3 2024 was positive at 28.66 million EGP.
Key lines against the same period a year earlier
This periodQ3 2023Change
Net profit32.04 million49.02 million−34.6%
Gross profit134 million137 million−1.9%
Total assets1.47 billion1.1 billion+33.9%
Total liabilities821 million559 million+46.8%
Shareholders' equity649 million538 million+20.5%
Total liabilities and equity1.47 billion1.1 billion+33.9%
Operating cash flow28.66 million19.43 million+47.5%
Investing cash flow-9.7 million-3.33 million−191.3%
Financing cash flow-17.05 million-18.75 million+9.1%
Net change in cash1.91 million-2.65 million+172.1%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy